FORMULATION OF IMMEDIATE RELEASE (IR) ATORVASTATIN CALCIUM PELLETS AND SUSTAINED RELEASE (SR) GLIBENCLAMIDE FOR FIXED-DOSE COMBINATION DOSAGE FORM

Authors

  • Kowshik K Department of Pharmaceutics, JSS College of Pharmacy, Sri Shivarathreeshwara Nagara, Mysuru, JSS Academy of Higher Education and Research, JSS Medical Institutions Campus, Sri Shivarathreeshwara Nagara, Mysuru, Karnataka, India.
  • Vishal Gupta N Department of Pharmaceutics, JSS College of Pharmacy, Sri Shivarathreeshwara Nagara, Mysuru, JSS Academy of Higher Education and Research, JSS Medical Institutions Campus, Sri Shivarathreeshwara Nagara, Mysuru, Karnataka, India.
  • Gowda Dv Department of Pharmaceutics, JSS College of Pharmacy, Sri Shivarathreeshwara Nagara, Mysuru, JSS Academy of Higher Education and Research, JSS Medical Institutions Campus, Sri Shivarathreeshwara Nagara, Mysuru, Karnataka, India.
  • Praveen Sivadasu Department of Pharmaceutics, JSS College of Pharmacy, Sri Shivarathreeshwara Nagara, Mysuru, JSS Academy of Higher Education and Research, JSS Medical Institutions Campus, Sri Shivarathreeshwara Nagara, Mysuru, Karnataka, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i12.26629

Keywords:

Multiple unit pellet system, Glibenclamide, Atorvastatin calcium, Sustained release, Immediate release

Abstract

Objective: The objective of the present research was to develop fixed-dose combinations for the treatment of dyslipidemia, associated with type-II diabetes mellitus for improvement of glucose tolerance.

Methods: Multiple unit pellet systems (MUPSs) consisting immediate release atorvastatin calcium pellets and sustained release glibenclamide were formulated by spheronization technique. The characterization of formulated pellets was done by Fourier transform infrared (FT-IR) and differential scanning calorimetry (DSC) studies, and formulated pellets were evaluated for solubility, viscosity, pH, and in vitro studies.

Results: From FT-IR and DSC studies, it was confirmed that no chemical interaction existed between the drug and the natural polymers used. Solubility of glibenclamide was found to be 4.38 and 18.24 and atorvastatin calcium was found to be 6.84, 214.67, and 287.43 g/L. The viscosity of 1% w/v of locust bean gum, guar gum, and ghatti gum was found to be 169 cP, 124 cP, and 31 cP in distilled water. The pH of locust bean gum, guar gum, and gum ghatti solutions was found to be 5.6±0.49, 5.2±0.27, and 4.7±0.51. The in vitro studies suggested that glibenclamide pellets had shown a sustained release till 12 h, while atorvastatin calcium had shown immediate release of drug due to rapid disintegration of pellets.

Conclusion: Thus, MUPS can be considered as an alternative approach to treat diabetes induced dyslipidemia.

Downloads

Download data is not yet available.

Author Biography

Kowshik K, Department of Pharmaceutics, JSS College of Pharmacy, Sri Shivarathreeshwara Nagara, Mysuru, JSS Academy of Higher Education and Research, JSS Medical Institutions Campus, Sri Shivarathreeshwara Nagara, Mysuru, Karnataka, India.

Professor

References

Almamory IA, Tsahel H. Detection level of urea, sugar, creatinine and hematology in patients of diabetic mellitus Type II. J Med Sci 2014;5:154-6.

American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-97.

Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-44.

McCarron P, Greenwood R, Elwood P, Shlomo YB, Bayer A, Baker I, et al. The incidence and aetiology of stroke in the caerphilly and speedwell collaborative Studies II: Risk factors of ischaemic stroke. Public Health 2001;115:12-20.

Deshpande RD, Gowda DV, Mahammad N. Design of Pistacia lentiscus (mastic gum) controlled release spheroids and investigating the influence of roll compaction. Ind Crops Prod 2013;44:603-10.

Papich MG. Saunders Handbook of Veterinary Drugs-E-Book: Small and Large Animal. St. Louis, Missouri, USA: Elsevier Health Sciences; 2015.

Kaplani AP, Malamataris S. Preparation and characterization of a new insoluble polymorphic form of glibenclamide. Int J Pharm 2000;195:239-46.

Ho JE, Paultre F, Mosca L. Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the women’s pooling project. Stroke 2003;34:2812-6.

Patel SA, Patel NG, Joshi AB. Multiple unit pellet system (MUPS) based fast disintegrating delayed-release tablets for pantoprazole delivery. Int J Pharm Pharm Sci 2018;10:77-84.

Higuchi T, Connors KA. Phase-solubility Techniques. Adv Anal Chem Instrum 1965;4:117-212.

Clarke GM, Newton JM, Short MD. Comparative gastrointestinal transit of pellet system of varying density. Int J Pharm 1995;114:1-11.

Du Pasquier A, Disma F, Bowmer T, Gozdz AS, Amatucci G, Tarascon JM. Differential scanning calorimetry studies of lithium ion and the reactivity of carbon anodes in plastic lithium ion batteries. J Electrochem Soc 1998;145:472-7.

Rojas J, Correa D. Comparative evaluation of the release properties of verapamil HCL and carbamazepine from microcrystalline cellulose II pellets. Int J Pharm Pharm Sci 2017;9:182-6.

Dash SK, Khan AS, Das SR, Padhan A, Rout D, Behera BC. Formulation and in-vitro evaluation of sustained released glibenclamide microspheres. Int J Pharm Sci Res 2012;3:1433-43.

Published

07-12-2018

How to Cite

K, K., V. Gupta N, G. Dv, and P. Sivadasu. “FORMULATION OF IMMEDIATE RELEASE (IR) ATORVASTATIN CALCIUM PELLETS AND SUSTAINED RELEASE (SR) GLIBENCLAMIDE FOR FIXED-DOSE COMBINATION DOSAGE FORM”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 12, Dec. 2018, pp. 159-65, doi:10.22159/ajpcr.2018.v11i12.26629.

Issue

Section

Original Article(s)

Most read articles by the same author(s)